A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (rt-PA) and Cerebrolysin in Acute Ischaemic Hemispheric Stroke.

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (rt-PA) and Cerebrolysin in Acute Ischaemic Hemispheric Stroke.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alteplase (Primary) ; FPF 1070 (Primary)
Indications Embolism and thrombosis; Stroke
Focus Therapeutic Use
Acronyms CERE-LYSE-1

Most Recent Events

19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
14 Feb 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com